Loading...
In 2013, Gilead Sciences launched Sovaldi, a hepatitis C cure, at $84,000 for a 12-week course — roughly $1,000 per pill. The drug actually worked: it cured over 95% of hepatitis C patients, eliminating a disease that had previously required decades of expensive management and often led to liver transplants costing $500,000 or more. By conventional cost-effectiveness analysis, $84,000 was a bargain compared to the lifetime cost of the disease. But the sticker price provoked outrage, congressional hearings, and a debate that exposed the fundamentally broken incentive structure of pharmaceutical pricing. The pricing logic operated on several mutually reinforcing layers. Drug companies invested heavily in R&D — Gilead spent roughly $11 billion developing Sovaldi (including the acquisition ...
Popular framing: Pharma companies are greedy and charge whatever they want.
Structural analysis: Patient and payer are decoupled, so demand-side price sensitivity vanishes; PBM rebates are paid as a percentage of list price, so the incentive runs toward higher list prices and bigger rebates; patent thickets and pay-for-delay deals neutralize the generic check. Every participant is individually rational while the system produces a 18%-of-GDP healthcare burden no actor chose.
Focusing on Gilead's greed obscures that any firm in its position would have made the same decision — the system selects for and rewards this behavior. Until the incentive architecture changes (reference pricing, negotiation power, conditional exclusivity tied to actual R&D costs), replacing individual actors changes nothing. The framing gap matters because moral outrage generates political energy but directs it at symptoms rather than the feedback loop that produces those symptoms.
